Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma

Journal of Surgical Oncology

Volumn 108, Issue 6, 2013, Pages 414-419

  Zhang, Yanhui ^a   Sun, Baocun ^a   Zhao, Xiulan ^a   Liu, Zhiyong ^a   Wang, Xudong ^a   Yao, Xin ^a   Dong, Xueyi ^a   Chi, Jiadong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

cancer stem like cells; microvessel density; renal cell carcinoma; vasculogenic mimicry

Indexed keywords

CD133 ANTIGEN; HERMES ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CANCER STEM LIKE CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROVASCULATURE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; VASCULOGENIC MIMICRY;

CANCER STEM-LIKE CELLS; MICROVESSEL DENSITY; RENAL CELL CARCINOMA; VASCULOGENIC MIMICRY;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD44; CARCINOMA, RENAL CELL; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886801522     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23402     Document Type: Article

References (41)

1. Karakiewicz PI, Briganti A, Chun FK, et al.: Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25: 1316-1322.
2. Mills EJ, Rachlis B, O'Regan C, et al.: Metastatic renal cell cancer treatments: An indirect comparison meta-analysis. BMC Cancer 2009; 9: 34.
3. Isbarn H, Karakiewicz PI:, Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr Opin Urol 2009; 19: 247-257.
4. Pardal R, Clarke MF, Morrison SJ:, Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL:, Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
6. Sagrinati C, Netti GS, Mazzinghi B, et al.: Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006; 17: 2443-2456.
7. Janikova M, Skarda J, Dziechciarkova M, et al.: Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 321-326.
8. Niu CS, Li MW, Ni YF, et al.: Effect of all-trans retinoic acid on the proliferation and differentiation of brain tumor stem cells. J Exp Clin Cancer Res 2010; 29: 113.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
10. Ma S, Chan KW, Hu L, et al.: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-2556.
11. Zou J, Yu XF, Bao ZJ, Dong J:, Proteome of human colon cancer stem cells: A comparative analysis. World J Gastroenterol 2011; 17: 1276-1285.
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al.: Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
13. Rentala S, Yalavarthy PD, Mangamoori LN:, Alpha1 and beta1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells. Asian J Androl 2010; 12: 548-555.
14. Lee CJ, Dosch J, Simeone DM:, Pancreatic cancer stem cells. J Clin Oncol 2008; 26: 2806-2812.
15. Bot PT, Hoefer IE, Piek JJ, Pasterkamp G:, Hyaluronic acid: Targeting immune modulatory components of the extracellular matrix in atherosclerosis. Curr Med Chem 2008; 15: 786-791.
16. Sehl ME, Sinsheimer JS, Zhou H, Lange KL:, Differential destruction of stem cells: Implications for targeted cancer stem cell therapy. Cancer Res 2009; 69: 9481-9489.
17. Shirakawa K, Wakasugi H, Heike Y, et al.: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002; 99: 821-828.
18. Liu W, Xu G, Ma J, et al.: Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma. Tohoku J Exp Med 2011; 224: 29-39.
19. Vartanian AA, Stepanova EV, Gutorov SL, et al.: Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. Can J Urol 2009; 16: 4726-4732.
20. Zhu P, Ning Y, Yao L, et al.: The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res 2010; 29: 124.
21. Li M, Gu Y, Zhang Z, et al.: Vasculogenic mimicry: A new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 2010; 16: 259-266.
22. Ricci-Vitiani L, Pallini R, Biffoni M, et al.: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828.
23. Wang R, Chadalavada K, Wilshire J, et al.: Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
24. Edge SB, Compton CC:, The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
25. Sun T, Zhao N, Zhao XL, et al.: Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry. Hepatology 2010; 51: 545-556.
26. Seftor RE, Hess AR, Seftor EA, et al.: Tumor cell vasculogenic mimicry: From controversy to therapeutic promise. Am J Pathol 2012; 181: 1115-1125.
27. Shen R, Ye Y, Chen L, et al.: Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE 2008; 3: e1652.
28. Florek M, Haase M, Marzesco AM, et al.: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005; 319: 15-26.
29. Pode-Shakked N, Metsuyanim S, Rom-Gross E, et al.: Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population. J Cell Mol Med 2009; 13: 1792-1808.
30. Zeppernick F, Ahmadi R, Campos B, et al.: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-129.
31. Schneider M, Huber J, Hadaschik B, et al.: Characterization of colon cancer cells: A functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer 2012; 12: 96.
32. Song W, Li H, Tao K, et al.: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008; 62: 1212-1218.
33. Sun B, Qie S, Zhang S, et al.: Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 2008; 39: 444-451.
34. Itzhaki O, Greenberg E, Shalmon B, et al.: Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS ONE 2013; 8: e57160.
35. Sun B, Zhang S, Zhang D, et al.: Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006; 16: 693-698.
36. Sabo E, Boltenko A, Sova Y, et al.: Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin Cancer Res 2001; 7: 533-537.
37. Herbst C, Kosmehl H, Stiller KJ, et al.: Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activity and occurrence of metastasis. J Cancer Res Clin Oncol 1998; 124: 141-147.
38. Kohler HH, Barth PJ, Siebel A, et al.: Quantitative assessment of vascular surface density in renal cell carcinomas. Br J Urol 1996; 77: 650-654.
39. Delahunt B, Bethwaite PB, Thornton A:, Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol 1997; 80: 401-404.
40. Weidner N:, Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow. J Pathol 1998; 184: 119-122.
41. Fox SB:, Tumour angiogenesis and prognosis. Histopathology 1997; 30: 294-301.